Argyle Capital Management Inc. decreased its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.7% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 159,573 shares of the biopharmaceutical company’s stock after selling 1,100 shares during the quarter. Pfizer makes up 2.2% of Argyle Capital Management Inc.’s holdings, making the stock its 3rd largest holding. Argyle Capital Management Inc.’s holdings in Pfizer were worth $5,360,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Asset Planning Services Ltd. lifted its stake in shares of Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. lifted its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer during the 1st quarter valued at $121,000. Cascade Investment Advisors Inc. lifted its stake in shares of Pfizer by 89.1% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares in the last quarter. Finally, Patten Group Inc. lifted its stake in shares of Pfizer by 5.1% during the 1st quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 252 shares in the last quarter. Institutional investors own 68.99% of the company’s stock.
Shares of Pfizer, Inc. (PFE) opened at 36.40 on Wednesday. The stock has a market cap of $216.48 billion, a PE ratio of 26.63 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.51. The firm has a 50-day moving average of $34.92 and a 200 day moving average of $33.71.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the business earned $0.64 earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.52%. Pfizer’s dividend payout ratio (DPR) is 94.12%.
In other news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last quarter, insiders sold 464,521 shares of company stock worth $15,813,961. Company insiders own 0.06% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/10/11/argyle-capital-management-inc-lowers-position-in-pfizer-inc-pfe.html.
A number of research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, September 19th. Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $35.00 to $39.00 in a research note on Wednesday, September 20th. Finally, Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and an average target price of $38.21.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.